Suchbegriff wählen

academia

ALDER HEY AND NEEDLESMART PARTNERSHIP AIMS TO REDUCE 100,000 NEEDLESTICK INJURIES TO NHS HEALTHCARE WORKERS

Liverpool, United Kingdom (OTS) - --News Direct-- BRITISH SMART MEDTECH COMPANY INVENTS WORLD’S FIRST END-TO-END SAFE NEEDLE DESTRUCTION TECHNOLOGY TECH AIMS TO REDUCE 3 MILLION GLOBAL NEEDLESTICK INJURIES In a recent survey*, it was reported that a staggering 94 per cent of practising surgeons in the UK have either been personally affected by a needlestick injury (NSI) or have seen a colleague experience one. The Royal College Of Nursing also reported last year that the pressures of the pandemic and lack of

Whole genome sequencing improves diagnosis of rare diseases and shortens diagnostic journeys for patients, according to world first study

London (ots/PRNewswire) - NB: SCIENCE MEDIA BRIEFING TAKING PLACE 14:00 GMT 9TH NOVEMBER 2021 - whole genome sequencing proved to be a better way to diagnose rare diseases than usual genomic testing methods - whole genome sequencing led to new rare disease diagnoses for NHS patients in some cases ending decades-long diagnostic odysseys - study represents significant step towards the goal of precision medicine - a transition that will have huge impact across the NHS and globally A world-first scientific study,

Call for climate protection for smallholders that produce one third of global food

Glasgow, Scotland (ots/PRNewswire) - UK boosts commitment to curtail agricultural emissions and reduce climate-induced loss and damage CGIAR urged global leaders today to ensure the 500 million smallholder farmers responsible for up to a third of global food production can adapt to climate change-induced loss and damage. Innovations are needed that can both reduce the contribution of global agriculture to climate change, and adapt to its increasingly evident consequences while also supporting livelihoods, nutrition and

Zentiva Advances Pharmaceutical Research Through ORBIS Project

Prague (ots/PRNewswire) - One of the missions that Zentiva has consistently pursued is to connect Academia and the Pharmaceutical Industry to accelerate drug development innovation and meet the unmet needs of the patients. Our company is pleased to resume the scientific exchange program as part of the ORBIS project, which was created within the largest EU grant programs HORIZON 2020, to connect European and American universities with Industrial partners at the scientific level. Thanks to the experience gained in the

Abcam completes $340m strategic acquisition and expands kit capacity and capability

Cambridge, England (ots/PRNewswire) - - Completing $340m strategic acquisition of BioVision - Expanding facilities in Eugene, further growing kits and assays portfolio - Supporting the growing demand of the sector and accelerating execution of strategic plan Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life sciences reagents and tools, today announces the successful completion of its acquisition of BioVision and the expansion of its immunoassay capacity in Eugene, OR. Across the life sciences sector, the

Can European Solutions Allow Equal Access to Rare Disease Drugs in All European Countries?

Wien (OTS) - The pool of patients suffering from an individual rare disease is very small. Drug development in this area is complex and the risk of failure is much higher than for other diseases. Basic research and the search for treatment options is neglected and often not deemed worth the investment. Ninety-five percent of all rare diseases are still without any treatment options. On October 1, 2021, panelists at the European Health Forum Gastein took a closer look at this issue and discussed potential future

Can European Solutions Allow Equal Access to Rare Disease Drugs in All European Countries?

Wien (OTS) - The pool of patients suffering from an individual rare disease is very small. Drug development in this area is complex and the risk of failure is much higher than for other diseases. Basic research and the search for treatment options is neglected and often not deemed worth the investment. Ninety-five percent of all rare diseases are still without any treatment options. On October 1, 2021, panelists at the European Health Forum Gastein took a closer look at this issue and discussed potential future

SC Johnson Invites Londoners to Walk Beneath the Ocean’s Surface in The Blue Paradox – An Immersive Experience Exploring the…

London (ots/PRNewswire) - Two-week educational event opens to the public (15-27th September) in White City, with free tickets available at BlueParadox.com SC Johnson, the maker of household consumer brands such as Mr Muscle®, Ecover® and Duck®, is launching The Blue Paradox, an immersive educational experience with 360-degree digital projections that invites the public to walk beneath the ocean's surface to explore the impact plastic waste has on our planet's most valuable natural resource and to better understand how

100+ Global Enterprises Take Advantage of Infosys Living Labs to Accelerate their Digital Innovation Agenda

Bengaluru, India (ots/PRNewswire) - Infosys Living Labs is delivering digital innovation as-a-service to help them meet next normal consumer expectations Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced that Infosys Living Labs is driving the digital innovation agenda for over 100 global enterprises. With Infosys Living Labs, businesses can leverage on-demand multi-tiered digital infrastructure, comprising technology, processes, people,

Merck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity

Darmstadt, Germany (ots/PRNewswire) - - Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years - Call for application for a global crowdsourcing project, 'Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging' Merck, a leading science and technology company, today announced the extension of its ongoing collaboration with BioMed X, Heidelberg, Germany. Under the new agreement, Merck will start up to six additional research projects at the